Core Insights - Pliant Therapeutics is undergoing a strategic restructuring, reducing its workforce by approximately 45% to extend its cash runway for late-stage clinical trials [1][3][4] - The company is awaiting topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast, expected in the second quarter of 2025, which will inform the next steps for the drug's development [2][3] Workforce Restructuring - The restructuring will impact all departments, but the company aims to maintain its late-stage clinical trial execution capabilities [3] - The process is expected to be substantially completed by the end of the second quarter of 2025 [3] Clinical Development - Bexotegrast is being developed for idiopathic pulmonary fibrosis (IPF) and has received Fast Track and Orphan Drug Designations from the FDA [4] - Pliant is also conducting a Phase 1 study for PLN-101095, targeting solid tumors, and has received clearance for a Phase 1 study of PLN-101325 for muscular dystrophies [4]